Drug · CHEMBL513
CARMUSTINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CARMUSTINE. Drugs and targets, record CHEMBL513. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL513
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- BCNU, Becenun, Bischloroethyl nitrosourea, Camustine, Carmubris, Carmustina, DTI-015, FDA-0345, NSC-409962, SK-27702, SRI-1720
- ChEMBL
- Open Targets' highest stage
- Approval, for 12 of its 67 diseases, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| GSR | Glutathione reductase, mitochondrial | Glutathione reductase inhibitor | INHIBITOR | https://conductscience.org/library/genes/2936 |
Source ChEMBL
Diseases67
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 67Source Open Targets
See all 67 diseasesTrials210
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00083551 | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | Phase 3 | 668 | 2015-09-22 | bcnu | Its name | ClinicalTrials.gov |
| NCT00345865 | Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma | Phase 2 | 473 | 2020-07-14 | carmustine | Its name | ClinicalTrials.gov |
| NCT00004031 | SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma | Phase 3 | 397 | 2021-02-02 | carmustine | Its name | ClinicalTrials.gov |
| NCT00004259 | Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas | Phase 3 | 230 | 2017-11-13 | carmustine | Its name | ClinicalTrials.gov |
| NCT01011920 | Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | Phase 2 | 227 | 2026-03-19 | carmustine | Its name | ClinicalTrials.gov |
| NCT00329030 | Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) | Phase 3 | 224 | 2016-06-10 | carmustine | Its name | ClinicalTrials.gov |
| NCT00281879 | Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer | Phase 2 | 200 | 2012-06-19 | carmustine | Its name | ClinicalTrials.gov |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | 174 | 2021-04-22 | carmustine | Its name | ClinicalTrials.gov | |
| NCT00388349 | Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | Phase 2 | 146 | 2017-06-14 | carmustine | Its name | ClinicalTrials.gov |
| NCT00695409 | Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 2 | 122 | 2018-07-06 | carmustine | Its name | ClinicalTrials.gov |
1 to 10 of 210
See all 210 trialsComparisons in its trials24
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Thalidomide vs No Thalidomide: serious adverse events | 323 of 323 | 345 of 345 | 668 | NCT00083551 | Trial comparisons |
| CHOP/CHOP-R x 3 vs CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant: deaths from any cause | 51 of 128 | 39 of 125 | 253 | NCT00004031 | Trial comparisons |
| CHOP/CHOP-R x 3 vs CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant: serious adverse events | 4 of 123 | 4 of 113 | 236 | NCT00004031 | Trial comparisons |
| B-BEAM vs R-BEAM: serious adverse events | 11 of 111 | 6 of 113 | 224 | NCT00329030 | Trial comparisons |
| Arm I vs Arm II: deaths from any cause | 11 of 54 | 15 of 54 | 108 | NCT01511562 | Trial comparisons |
| Arm I vs Arm II: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | 54 of 54 | 53 of 54 | 108 | NCT01511562 | Trial comparisons |
| Arm I vs Arm II: serious adverse events | 21 of 54 | 33 of 54 | 108 | NCT01511562 | Trial comparisons |
| MATRIX - R-ICE - Conditioning and ASCT vs Enrolled, But Not Treated: deaths from any cause | 50 of 75 | 1 of 4 | 79 | NCT02329080 | Trial comparisons |
| MATRIX - R-ICE - Conditioning and ASCT vs Enrolled, But Not Treated: serious adverse events | 46 of 75 | 0 of 4 | 79 | NCT02329080 | Trial comparisons |
| Irradiation in Conditioning vs Carmustine in Conditioning: Short-term and Long-term Treatment-related Toxicities | 39 of 55 | 1 of 5 | 60 | NCT00559104 | Trial comparisons |
1 to 10 of 24
See all 24 comparisons in its trialsPapers from its trials104
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials3
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Digit Span Test | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 1 | ConductCognition |
| Verbal Learning | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL513
GET https://conductscience.org/api/drugs/v1/CHEMBL513/diseases?page=2